Keywords: Genzyme, Renvela, PPB, Kidney disease, Research

Genzyme’s woes continue as it drops investigational APB follow-up for Renvela, after poor trial results

Article | 19 November 2009

Print This

US biotechnology major Genzyme has reported results of a Phase II/III study of its advanced phosphate binder (APB), a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in